<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">0376374</journal-id><journal-id journal-id-type="pubmed-jr-id">5331</journal-id><journal-id journal-id-type="nlm-ta">J Urol</journal-id><journal-id journal-id-type="iso-abbrev">J Urol</journal-id><journal-title-group><journal-title>The Journal of urology</journal-title></journal-title-group><issn pub-type="ppub">0022-5347</issn><issn pub-type="epub">1527-3792</issn></journal-meta><article-meta><article-id pub-id-type="pmid">36006050</article-id><article-id pub-id-type="pmc">9933910</article-id><article-id pub-id-type="doi">10.1097/JU.0000000000002902</article-id><article-id pub-id-type="manuscript">NIHMS1872197</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De</surname><given-names>Brian</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Pasalic</surname><given-names>Dario</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Barocas</surname><given-names>Daniel A.</given-names></name><degrees>MD, MPH</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wallis</surname><given-names>Christopher J.D.</given-names></name><degrees>MD, PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Li-Ching</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Zhiguo</given-names></name><degrees>MS</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Koyama</surname><given-names>Tatsuki</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Chad</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Conwill</surname><given-names>Ralph</given-names></name><degrees>BS</degrees><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Goodman</surname><given-names>Michael</given-names></name><degrees>MD, MPH</degrees><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Hamilton</surname><given-names>Ann S.</given-names></name><degrees>PhD, MA</degrees><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xiao-Cheng</given-names></name><degrees>MD, MPH</degrees><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Paddock</surname><given-names>Lisa E.</given-names></name><degrees>PhD, MPH</degrees><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Stroup</surname><given-names>Antoinette</given-names></name><degrees>PhD</degrees><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Cooperberg</surname><given-names>Matthew R.</given-names></name><degrees>MD, MPH</degrees><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Hashibe</surname><given-names>Mia</given-names></name><degrees>PhD</degrees><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Neil</surname><given-names>Brock B.</given-names></name><degrees>MD</degrees><xref rid="A12" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Sherrie H.</given-names></name><degrees>PhD, MS, MPH</degrees><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name><surname>Greenfield</surname><given-names>Sheldon</given-names></name><degrees>MD</degrees><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name><surname>Penson</surname><given-names>David F.</given-names></name><degrees>MD, MPH</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name><surname>Hoffman</surname><given-names>Karen E.</given-names></name><degrees>MD, MHSc, MPH</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="CR1" ref-type="corresp">**</xref></contrib></contrib-group><aff id="A1"><label>1</label>The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX;</aff><aff id="A2"><label>2</label>Vanderbilt University Medical Center, Department of Urology, Nashville, TN;</aff><aff id="A3"><label>3</label>Mount Sinai Hospital, Division of Urology, Department of Surgery, University of Toronto, Toronto, ON;</aff><aff id="A4"><label>4</label>Vanderbilt University Medical Center, Department of Biostatistics, Nashville, TN;</aff><aff id="A5"><label>5</label>Vanderbilt University Medical Center, Office of Patient and Community Education, Patient Advocacy Program, Vanderbilt Ingram Cancer Center, Nashville, TN;</aff><aff id="A6"><label>6</label>Emory University Rollins School of Public Health, Department of Epidemiology, Atlanta, GA;</aff><aff id="A7"><label>7</label>Keck School of Medicine at the University of Southern California, Department of Preventative Medicine, Los Angeles, CA;</aff><aff id="A8"><label>8</label>Louisiana State University New Orleans School of Public Health, Department of Epidemiology, New Orleans, LA;</aff><aff id="A9"><label>9</label>Cancer Institute of New Jersey, Rutgers Health, Department of Epidemiology, New Brunswick, NJ;</aff><aff id="A10"><label>10</label>University of California San Francisco, Department of Urology, San Francisco, CA;</aff><aff id="A11"><label>11</label>University of Utah School of Medicine, Department of Family and Preventative Medicine, Salt Lake City, UT;</aff><aff id="A12"><label>12</label>University of Utah Health, Department of Urology, Salt Lake City, UT;</aff><aff id="A13"><label>13</label>University of California Irvine, Department of Medicine, Irvine, CA</aff><aff id="A14"><label>14</label>Geriatric Research Education and Clinical Center, Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN</aff><author-notes><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">These authors contributed equally</p></fn><fn fn-type="con" id="FN2"><p id="P2">Author contributions:</p><p id="P3"><bold>Brian De:</bold> Conceptualization, Data curation, writing&#x02013;original draft, and writing&#x02013;review and editing.</p><p id="P4"><bold>Dario Pasalic:</bold> Conceptualization, data curation, writing&#x02013;original draft, and writing&#x02013;review and editing.</p><p id="P5"><bold>Daniel A. Barocas:</bold> Conceptualization, data curation, funding acquisition, investigation, methodology, writing&#x02013;original draft, and writing&#x02013;review and editing.</p><p id="P6"><bold>Li-Ching Huang:</bold> Data curation, formal analysis, writing&#x02013;original draft, and writing&#x02013;review and editing.</p><p id="P7"><bold>Zhiguo Zhao:</bold> Data curation, formal analysis, writing&#x02013;original draft, and writing&#x02013;review and editing.</p><p id="P8"><bold>Tatsuki Koyama:</bold> Data curation, formal analysis, writing&#x02013;original draft, and writing&#x02013;review and editing.</p><p id="P9"><bold>Chad Tang:</bold> Writing&#x02013;review and editing.</p><p id="P10"><bold>Ralph Conwill:</bold> Writing&#x02013;review and editing.</p><p id="P11"><bold>Michael Goodman:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P12"><bold>Ann S. Hamilton:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P13"><bold>Xiao-Cheng Wu:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P14"><bold>Lisa E. Paddock:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P15"><bold>Antoinette M. Stroup:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P16"><bold>Matthew R. Cooperberg:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P17"><bold>Mia Hashibe:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P18"><bold>Brock B. O&#x02019;Neil:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P19"><bold>Sherrie H. Kaplan:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P20"><bold>Sheldon Greenfield:</bold> Investigation, methodology, and writing&#x02013;review and editing.</p><p id="P21"><bold>David F. Penson:</bold> Conceptualization, data curation, funding acquisition, investigation, methodology, and writing&#x02013;review and editing.</p><p id="P22"><bold>Karen E. Hoffman:</bold> Conceptualization, data curation, writing&#x02013;original draft, and writing&#x02013;review and editing.</p></fn><corresp id="CR1"><label>**</label><underline>Corresponding author</underline>: Dr. Karen E. Hoffman. The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology. 1515 Holcombe Blvd Unit 1422, Houston, TX 77030. Phone: 713-563-2339. <email>KHoffman1@mdanderson.org</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>10</day><month>2</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>25</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>12</month><year>2023</year></pub-date><volume>208</volume><issue>6</issue><fpage>1226</fpage><lpage>1239</lpage><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P23">Data comparing radical prostatectomy (RP) and external beam radiation therapy with low-dose rate brachytherapy boost (EBRT-LDR) are lacking. To better guide shared decision-making regarding treatment, we compared patient reported outcomes (PROs) through 5 years following RP or EBRT-LDR for localized prostate cancer.</p></sec><sec id="S2"><title>Methods:</title><p id="P24">From 2011&#x02013;2012, men aged &#x0003c; 80 years with localized prostate adenocarcinoma were enrolled and followed longitudinally. PROs included the Expanded Prostate Index Composite. Regression models adjusted for baseline scores and covariates were constructed.</p></sec><sec id="S3"><title>Results:</title><p id="P25">The study population included 112 men treated with EBRT-LDR and 1553 treated with RP. Compared to RP, EBRT-LDR was associated with clinically meaningful worse urinary irritative/obstructive (adjusted mean score difference [95% confidence interval]: &#x02212;5.0 [&#x02212;8.7, &#x02212;1.3]; P=0.008 at 5 years) and better urinary incontinence function (13.3 [7.7, 18.9]; <italic toggle="yes">P</italic>&#x0003c;0.001 at 5 years) through 5 years. Urinary function bother was similar between groups (<italic toggle="yes">P</italic>&#x0003e;0.4 at all timepoints). Treatment with EBRT-LDR was associated with worse bowel function (&#x02212;4.0 [&#x02212;6.9, &#x02212;1.1]; <italic toggle="yes">P</italic>=0.006 at 5 years) through 5 years compared to RP. Treatment with EBRT-LDR was associated with better sexual function at 1 year (12.0 [6.5, 17.5]; <italic toggle="yes">P</italic>&#x0003c;0.001 at 1 year) compared to RP, but there was insufficient evidence to reject the supposition that no difference was seen at 3 or 5 years.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P26">Compared to RP, EBRT-LDR was associated with clinically meaningful worse urinary irritative/obstructive and bowel functions but better urinary incontinence function through 5 years after treatment. These patient-reported functional outcomes may clarify treatment expectations and help inform treatment choices for localized prostate cancer.</p></sec></abstract><kwd-group><title>Keywords (MeSH)</title><kwd>patient reported outcome measures</kwd><kwd>radical prostatectomy</kwd><kwd>low dose rate brachytherapy</kwd></kwd-group></article-meta></front><body><sec id="S5"><title>Introduction</title><p id="P27">Radical prostatectomy (RP) is the most commonly used treatment in the United States for intermediate-risk and high-risk localized prostate cancer.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Since the publication of the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) randomized trial, there has been increasing interest in dose-escalated radiotherapy combining external beam radiation therapy (EBRT), low dose-rate (LDR) brachytherapy boost, and androgen deprivation therapy (ADT).<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p><p id="P28">Prospective studies comparing RP and EBRT with brachytherapy boost (BT) are lacking and retrospective studies provide conflicting evidence regarding impacts on prostate cancer-specific survival (PCSS) and overall survival (OS).<sup><xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref></sup> In the absence of high-quality evidence regarding survival differences between the treatments, assessments of functional outcomes and health-related quality-of-life (HRQoL) are crucial for patient selection and education. Longitudinal data on patient-reported outcomes (PROs) better enable patients to make evidenced-based and well-informed treatment decisions that are concordant with their values and preferences.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Comparisons of functional outcomes or HRQoL between patients treated with RP or EBRT-LDR have not been reported.<sup><xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R6" ref-type="bibr">6</xref></sup> To address the existing gaps in knowledge, we evaluated a prospective cohort of patients treated with contemporary surgical and radiation therapy techniques to compare PROs&#x02014;including function, treatment regret, and QoL&#x02014;between RP and EBRT-LDR over 5 years of follow up.</p></sec><sec id="S6"><title>Materials &#x00026; Methods</title><sec id="S7"><title>Study population</title><p id="P29">Men with localized prostate cancer were enrolled in Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR), a multi-site prospective study (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01326286" ext-link-type="uri">NCT01326286</ext-link>).<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Enrollment occurred from 2011&#x02013;2012 among men younger than 80 years of age with a prostate-specific antigen (PSA) of &#x0003c;50 ng/dL, and diagnosis of a pathologically-confirmed localized prostate adenocarcinoma within 6 months of study participation. Enrollment occurred at five SEER registry areas and was augmented by the addition of patients from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Institutional review board approval was obtained at each study site, and all participants provided informed consent. Medical records were abstracted for tumor characteristics, PSA levels, and treatment history.</p></sec><sec id="S8"><title>Outcome measures</title><p id="P30">CEASAR captured patient demographic data and PROs through surveys at baseline, 6 months, and 1, 3, and 5 years. Surveys included the 26-item Expanded Prostate Cancer Index Composite (EPIC) which captures functional domains specific to prostate cancer treatment adverse effects; the 36-item Short Form Health Survey (SF36) which captures HRQoL domains; and the Clark 5-item treatment-related regret scale.<sup><xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup> Additional questionnaires included the Total Illness Burden Index for Prostate Cancer (TIBI-CaP), Participatory Decision-Making Scale (PDMS), Provider-Dependent Health Care Orientation Scale (PDHCOS), Center for Epidemiologic Studies Depression Scale (CES-D), and the Medical Outcomes Study Social Support Scale (MOS).<sup><xref rid="R15" ref-type="bibr">15</xref>&#x02013;<xref rid="R19" ref-type="bibr">19</xref></sup></p></sec><sec id="S9"><title>Minimal clinically important differences</title><p id="P31">The minimal clinically important differences (MCIDs) in points for EPIC domains (5&#x02013;7 urinary irritation; 6&#x02013;9 urinary incontinence; 4&#x02013;6 bowel function; and 10&#x02013;12 sexual function) and SF36 domains (7 physical function; 6 emotional well-being; and 9 energy/fatigue) were adapted from previous publications that used an anchor-based and distribution-based approach<sup><xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R20" ref-type="bibr">20</xref></sup></p></sec><sec id="S10"><title>Statistical analysis</title><p id="P32">Demographic and clinical characteristics were summarized with median and quartiles for continuous variables, or frequency and percentage for categorical variables. Treatment group (i.e., EBRT-LDR vs. RP) differences were summarized with Wilcoxon rank-sum or Pearson chi-squared tests. The primary outcome (i.e., EPIC and SF36 domain scores) was summarized with median values and quartiles for each group. In order to determine differences between groups, multivariable longitudinal linear regressions were used and reported as adjusted mean score differences with 95% confidence intervals (CIs). The secondary outcomes were selected <italic toggle="yes">a priori</italic> among patient rating of individual problems and examined using longitudinal logistic regression models with results expressed as adjusted odds ratios (aORs) and the corresponding 95% CIs. All multivariable models adjusted for age (continuous, restricted-cubic-splines), race, TIBI-CaP, D&#x02019;Amico risk classification, androgen deprivation therapy (ADT) within 1 year after treatment, PDHCOS (continuous, linear), PDMS (continuous, linear), MOS (continuous, linear), CES-D (continuous, linear), time from treatment (continuous, restricted-cubic-splines), site of treatment, baseline SF-36 physical function score (continuous, linear) if outcome is EPIC-26, and other corresponding baseline domain scores (continuous, restricted-cubic-splines). The Huber&#x02013;White method was used to estimate the robust variance-covariance matrix to account for missing values for covariates.<sup><xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref></sup> The multiple-imputation chained-equations method was utilized in all regression models to account for missing values for covariates; no outcome variables were imputed.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> Two-sided <italic toggle="yes">P</italic>-values less than 0.05 were considered statistically significant. All analyses were conducted using R version-4.0. The findings, especially for secondary analyses, should be interpreted as exploratory rather than confirmatory considering the large number of estimates that are reported.</p></sec></sec><sec id="S11"><title>Results</title><sec id="S12"><title>Participants and clinical characteristics</title><p id="P33">The analysis dataset included 1645 men: 112 in the EBRT-LDR group and 1553 in the RP group. Response rates at 6 months, 1, 3, and 5 years were 95%, 93%, 85%, and 77%, respectively (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1</xref>). The median follow-up for vital status was 73 months [63, 79]. Baseline characteristics of study participants are summarized in <xref rid="T1" ref-type="table">Table 1</xref>. EBRT-LDR patients were older, more likely to be Black, more commonly had high-risk disease and were more likely to have received ADT in the first year after treatment. A subgroup analysis of patients with favorable and unfavorable disease characteristics demonstrated similar differences (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1</xref>).</p><p id="P34">Most men (91%) treated with RP underwent nerve-sparing procedures, most of which were bilateral (79%). Men who received EBRT-LDR were prescribed a median EBRT dose of 45.0 Gy [45.0, 52.5] to the prostate; LDR boost was prescribed as Iodine-125 (I-125) to a median dose of 90.0 Gy [80.0, 110.0] in 86 men and Palladium-103 (Pd-103) to a median dose of 100.0Gy [92.5, 100.0] in 16 men.</p></sec><sec id="S13"><title>Urinary irritative/obstructive</title><p id="P35">Baseline urinary irritative/obstructive function did not differ between groups. A clinically meaningful <italic toggle="yes">decline</italic> in urinary irritative/obstructive function (MCID 5&#x02013;7 points) was reported by men undergoing EBRT-LDR, from a baseline median of 91 points to 75 at 6 months and 81 at 1 year, followed by improvement to 88 at 3 years and 5 years). A clinically meaningful <italic toggle="yes">improvement</italic> in urinary irritative/obstructive function was reported by men undergoing RP, from a baseline median of 88 points to 94 at all subsequent follow-ups (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="T2" ref-type="table">Table 2</xref>).</p><p id="P36">When controlling for baseline scores and other covariates, treatment with EBRT-LDR was associated with clinically meaningful <italic toggle="yes">worse</italic> urinary irritative function compared to treatment with RP through 5 years. Men in the EBRT-LDR group were <italic toggle="yes">more likely</italic> to report moderate-or-big problems with frequent urination symptoms through 3 years followed by resolution at 5 years; and moderate-or-big problems with burning with urination symptoms through 3 years followed by resolution at 5 years. There was insufficient evidence to reject the supposition that there was no difference in urinary function bother (<xref rid="F2" ref-type="fig">Figure 2</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p></sec><sec id="S14"><title>Urinary incontinence</title><p id="P37">Baseline urinary incontinence function did not differ between groups. A clinically meaningful <italic toggle="yes">decline</italic> in urinary incontinence function (MCID 6&#x02013;9 points) was reported by men undergoing EBRT-LDR, from a baseline median of 100 points to a median of 92 at 5 years. A clinically meaningful <italic toggle="yes">decline</italic> in urinary incontinence function was reported by men undergoing RP, from a baseline median of 100 points to 73 at 5 years (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="T2" ref-type="table">Table 2</xref>).</p><p id="P38">When controlling for baseline scores and other covariates, treatment with EBRT-LDR was associated with clinically meaningful <italic toggle="yes">better</italic> urinary incontinence function compared to treatment with RP through 5 years. Treatment with EBRT-LDR was <italic toggle="yes">inversely</italic> associated with problems with moderate-or-big urinary leakage symptoms through 1 year followed by resolution at 3 years. Men who underwent EBRT-LDR were <italic toggle="yes">less likely</italic> to report using one-or-more pads through 5 years (<xref rid="F2" ref-type="fig">Figure 2</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p></sec><sec id="S15"><title>Bowel function</title><p id="P39">Baseline bowel function did not differ between groups (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="T2" ref-type="table">Table 2</xref>). A clinically meaningful <italic toggle="yes">decline</italic> in bowel function (MCID 4&#x02013;6 points) was reported by men undergoing EBRT-LDR, from a baseline median of 100 points to 92 at 5 years. A clinically meaningful change was not observed for men undergoing RP.</p><p id="P40">When controlling for baseline scores and other covariates, treatment with EBRT-LDR (<xref rid="F2" ref-type="fig">Figure 2</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>) was associated with clinically meaningful <italic toggle="yes">worse</italic> bowel function compared to treatment with RP through 5 years. Treatment with EBRT-LDR was <italic toggle="yes">more likely</italic> to be associated with problems with moderate-or-big bloody stool symptoms through 1 year followed by resolution at 3 years and problems with moderate-or-big bowel urgency symptoms through 3 years followed by resolution at 5 years. Despite these associations, the absolute rate of moderate-or-big problems with bloody stools was &#x02264;2% for both treatment groups through 5 years, and the absolute rate of moderate-to-big bowel urgency symptoms was 6% for patients treated with EBRT-LDR and 3% for patients treated with RP at 5 years. No statistically significant difference was observed in bowel function bother.</p></sec><sec id="S16"><title>Sexual function</title><p id="P41">Baseline sexual function (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="T2" ref-type="table">Table 2</xref>) was <italic toggle="yes">lower</italic> in the EBRT-LDR vs. RP group (65 [33, 85] vs. 78 [38, 95]; <italic toggle="yes">P</italic>=0.016). A clinically meaningful <italic toggle="yes">decline</italic> in sexual function (MCID 10&#x02013;12) was reported by men undergoing EBRT-LDR, from a baseline median of 65 points to 38 at 5 years. A clinically meaningful <italic toggle="yes">decline</italic> in sexual function was reported by men undergoing RP, from a baseline median of 78 points to 35 at 5 years.</p><p id="P42">When controlling for baseline scores and other covariates, treatment with EBRT-LDR was associated with clinically meaningful <italic toggle="yes">better</italic> sexual function compared with treatment with RP through 1 year followed by resolution at 3 years which was statistically, but not clinically, significant. Treatment with EBRT-LDR was <italic toggle="yes">less likely</italic> to result in problems with moderate-or-big sexual bother through 1 year followed by resolution at 3 years; or lead to insufficient erections through 5 years (<xref rid="F2" ref-type="fig">Figure 2</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p></sec><sec id="S17"><title>Hormonal function</title><p id="P43">Baseline hormone function did not differ between groups (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="T2" ref-type="table">Table 2</xref>). A clinically meaningful <italic toggle="yes">decline</italic> in hormone function (MCID 4&#x02013;6) was reported by men undergoing EBRT-LDR, from a baseline median of 95 points to 90 at 6 months and 1 year, followed by improvement to 95 at years 3 and 5. A clinically meaningful change in hormone function was not reported by men undergoing RP. When controlling for baseline scores and other covariates, there was no clinically meaningful difference in hormone function through 5 years (<xref rid="F2" ref-type="fig">Figure 2</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p></sec><sec id="S18"><title>Health-related quality-of-life</title><p id="P44">Baseline SF36 emotional well-being (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>) was <italic toggle="yes">higher</italic> in the EBRT-LDR vs. RP group. Otherwise, there were no baseline differences in SF36 physical function or energy/fatigue. When controlling for baseline scores and other covariates, there were no clinically meaningful differences between treatment groups in physical function (MCID 7), emotional well-being (MCID 6), or energy/fatigue (MCID 9) through 5 years (<xref rid="F3" ref-type="fig">Figure 3</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>).</p></sec><sec id="S19"><title>Patient-reported treatment-related regret</title><p id="P45">There was no significant difference in treatment-related regret between RP and EBRT-LDR (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref>).</p></sec></sec><sec id="S20"><title>Discussion</title><p id="P46">In this prospective cohort study of men with localized prostate cancer, we observed that patients treated with EBRT-LDR and RP continued to have distinct adverse event profiles through 5 years of treatment. Specifically, EBRT-LDR was associated with clinically meaningful worse urinary irritative/obstructive and bowel function and RP was associated with clinically meaningful worse urinary incontinence function. Importantly, though these differences were statistically significant and clinically meaningful, their magnitudes substantially attenuated by 5 years. Compared with RP, EBRT-LDR was also associated with better sexual function at 1 year but no statistically significant difference was seen at 3 or 5 years. There were no clinically meaningful differences in physical function, emotional well-being, energy/fatigue, or treatment-related regret through 5 years.</p><p id="P47">Studies comparing HRQoL for patients receiving RP vs. EBRT + BT boost are limited. One study examined functional outcomes for patients undergoing RP vs. EBRT + high-dose rate (HDR) boost and found no significant differences between treatment groups for any HRQoL variables.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> No comparisons of functional outcomes between RP and EBRT-LDR have been published and no randomized trials directly comparing these modalities are ongoing. However, studies comparing EBRT + BT boost to EBRT alone may help put our findings in context. The ASCENDE-RT trial, which compared dose escalated EBRT &#x000b1; LDR boost for intermediate- and high-risk disease, utilized the SF36v2 survey to assess HRQoL. At 6-year follow up, patients who received EBRT-LDR plus ADT were more likely to experience physician-reported grade &#x02265;3 genitourinary toxicity and worse declines in patient-reported urinary function and physical function vs. those who received EBRT plus ADT.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> These results mirror the comparisons of EBRT-LDR with RP in the current study, which show persistence of urinary irritative/obstructive symptoms through 5 years for patients receiving EBRT-LDR. Parry et al. reported on patient-reported functional outcomes following EBRT &#x000b1; HDR boost based on English cancer registry data linked to a survey sent to patients. The study showed that, vs. EBRT alone, EBRT + HDR boost resulted in worse urinary irritation/obstruction scores (adjusted difference &#x02212;6.1 [&#x02212;8.8, &#x02212;3.4]) as assessed by EPIC. Given that surveys were administered at non-uniform times and that only a minority of surveys (33%) had follow up &#x02265; 18 months, a longitudinal relationship between irritative/obstructive symptoms and treatment with EBRT + HDR is difficult to determine from this study. Additionally, the generalizability of these findings to EBRT-LDR is uncertain.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> In the present analysis, the largest difference in irritative/obstructive symptoms between EBRT-LDR and RP was observed at 6 months and this difference lessened over time but remained both statistically and clinically significant in favor of RP through 5 years. Notably, urinary function and bowel function <italic toggle="yes">bother</italic> were similar between the two groups at 5 years. Several studies have compared PROs for patients treated with RP vs. EBRT monotherapy, BT monotherapy, or active surveillance and have shown worse erectile dysfunction and urinary incontinence for RP vs. other treatments, as well as equivalent or worse bowel symptoms for patients treated with EBRT or BT monotherapy vs. other treatments.<sup><xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref></sup></p><p id="P48">This study has several limitations. First, comparisons of RP and EBRT-LDR in prostate cancer may be affected by confounding by external factors. While we attempted to account for differences between groups in a multivariable regression model, confounding likely extends beyond attributes evaluated or captured in this study. Second, missing survey data may also contribute to bias, especially if the data are not missing at random; although we attempted to account for this using multiple imputation methods for independent variables. Third, this population-based cohort included patients treated with EBRT-LDR without standardization of dose, fractionation, or technique. The median I-125 dose in this cohort was lower than consensus guideline doses and those used in the ASCENDE-RT trial, which may have attenuated the toxicities seen.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Fourth, data regarding the brachytherapy technique, including the use of rectal spacers, planning technique, seed placement approach, and dosimetric parameters to the target volumes and organs at risk were not prospectively captured in this database, making it challenging to contextualize the toxicity seen in the EBRT-LDR group. Additionally, this study did not enroll patients who received HDR brachytherapy, which is associated in other contexts with more favorable QoL and toxicity outcomes than LDR.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Similarly, patients treated with LDR monotherapy, used by some even for high-risk disease<sup><xref rid="R30" ref-type="bibr">30</xref></sup>, were not included. As such, these results are not generalizable to EBRT-HDR or LDR monotherapy treatment, both of which may be associated with superior QoL outcomes than those described for EBRT-LDR. Fifth, 77% of all EBRT-LDR patients were enrolled at a single center, potentially limiting the generalizability of these results. While physician-level data were not collected, it is possible that these patients were treated by relatively few brachytherapists, potentially further limiting generalizability. Sixth, many patients with low-risk disease received interventions in the current study. While treatment of low-risk disease was a more common practice at the time of study enrollment, this may limit generalizability given that current guidelines favor active surveillance for these patients. Seventh, unmatched baseline characteristics or differential non-response bias between the cohorts may have led us to fail to identify a true advantage in sexual function associated with EBRT-LDR vs. RP; though sexual function scores were similar at 5 years, baseline sexual function was higher and the decline was greater in the RP cohort (RP: 78 at baseline, 35 at 5 years; EBRT-LDR: 65 at baseline, 38 at 5 years). Finally, this study considers data through 5 years following treatment, which is expected to capture the majority of functional change a patient may experience; however, it is possible that the data may insufficiently capture late effects. Ten-year data are forthcoming.</p><p id="P49">In conclusion, in this prospective cohort of men with localized prostate cancer, EBRT-LDR was associated with clinically meaningful worse bowel and worse urinary irritative/obstructive function and RP was associated with worse urinary incontinence function through 5 years. Despite these differences, however, urinary function bother was similar between groups. These findings may clarify treatment expectations and help men make informed treatment choices for their localized prostate cancer.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>Supplement</label><media xlink:href="NIHMS1872197-supplement-Supplement.docx" id="d64e708" position="anchor"/></supplementary-material></sec></body><back><ack id="S22"><title>Funding:</title><p id="P51">This study was supported by the Agency for Healthcare Research and Quality (1R01HS019356, 1R01HS022640), the Patient-Centered Outcomes Research Institute (CE-12-11-4667) and the National Cancer Institute (R01CA230352). This work was also supported in part by the Cancer Center Support Grant (NCI Grant P30 CA016672). Data management was facilitated by Vanderbilt University&#x02019;s Research Electronic Data Capture (REDCap) system, which is supported by the Vanderbilt Institute for Clinical and Translational Research grant (UL1TR000445 from National Center for Advancing Translational Sciences). Additional support was provided by the Utah Cancer Registry, which is funded by the National Cancer Institute&#x02019;s SEER Program, Contract No. HHSN261201800016I, the US Centers for Disease Control and Prevention&#x02019;s National Program of Cancer Registries, Cooperative Agreement No. NU58DP006320, with additional support from the University of Utah and Huntsman Cancer Foundation.</p></ack><fn-group><fn id="FN3"><p id="P52"><bold>Ethical approval:</bold> All procedures performed in the study were in accordance with the ethical standards of the local research committee and the 1964 Helsinki Declaration and its later amendments.</p></fn><fn id="FN4"><p id="P53"><bold>Informed consent:</bold> Informed consent was obtained from patients at the initiation of the study.</p></fn></fn-group><sec sec-type="data-availability" id="S21"><title>Availability of Data and Material:</title><p id="P50">Due to the nature of this research, participants of this study did not agree for their individual data to be shared publicly, so supporting data is not available.</p></sec><glossary><title>Abbreviations and acronyms</title><def-list><def-item><term>ADT</term><def><p id="P54">androgen deprivation therapy</p></def></def-item><def-item><term>ASCENDE-RT</term><def><p id="P55">Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy</p></def></def-item><def-item><term>BT</term><def><p id="P56">brachytherapy</p></def></def-item><def-item><term>CaPSURE</term><def><p id="P57">Cancer of the Prostate Strategic Urologic Research Endeavor</p></def></def-item><def-item><term>CEASAR</term><def><p id="P58">Comparative Effectiveness Analysis of Surgery and Radiation</p></def></def-item><def-item><term>CES-D</term><def><p id="P59">Center for Epidemiologic Studies Depression Scale</p></def></def-item><def-item><term>EBRT</term><def><p id="P60">external beam radiation therapy</p></def></def-item><def-item><term>EPIC</term><def><p id="P61">Expanded Prostate Cancer Index Composite</p></def></def-item><def-item><term>FACT-G</term><def><p id="P62">Functional Assessment of Cancer Therapy-General</p></def></def-item><def-item><term>FACT-P</term><def><p id="P63">Functional Assessment of Cancer Therapy-Prostate</p></def></def-item><def-item><term>HDR</term><def><p id="P64">high dose rate</p></def></def-item><def-item><term>HRQoL</term><def><p id="P65">health-related quality of life</p></def></def-item><def-item><term>I-125</term><def><p id="P66">iodine-125</p></def></def-item><def-item><term>LDR</term><def><p id="P67">low dose rate</p></def></def-item><def-item><term>MCID</term><def><p id="P68">minimal clinically important difference</p></def></def-item><def-item><term>MOS</term><def><p id="P69">Medical Outcomes Study Social Support Scale</p></def></def-item><def-item><term>NCDB</term><def><p id="P70">National Cancer Data Base</p></def></def-item><def-item><term>OS</term><def><p id="P71">overall survival</p></def></def-item><def-item><term>PCSS</term><def><p id="P72">prostate cancer-specific survival</p></def></def-item><def-item><term>Pd-103</term><def><p id="P73">palladium-103</p></def></def-item><def-item><term>PDHCOS</term><def><p id="P74">Provider-Dependent Health Care Orientation Scale</p></def></def-item><def-item><term>PDMS</term><def><p id="P75">Participatory Decision-Making Scale</p></def></def-item><def-item><term>PRO</term><def><p id="P76">patient-reported outcomes</p></def></def-item><def-item><term>PSA</term><def><p id="P77">prostate specific antigen</p></def></def-item><def-item><term>QoL</term><def><p id="P78">quality of life</p></def></def-item><def-item><term>RP</term><def><p id="P79">radical prostatectomy</p></def></def-item><def-item><term>SEER</term><def><p id="P80">Surveillance, Epidemiology, and End Results</p></def></def-item><def-item><term>SF36</term><def><p id="P81">36-item Short Form Health Survey</p></def></def-item><def-item><term>TIBI-CaP</term><def><p id="P82">Total Illness Burden Index for Prostate Cancer</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Burt</surname><given-names>LM</given-names></name>, <name><surname>Shrieve</surname><given-names>DC</given-names></name>, <name><surname>Tward</surname><given-names>JD</given-names></name>: <article-title>Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database</article-title>. <source>Adv Radiat Oncol</source>, <volume>3</volume>: <fpage>170</fpage>, <year>2018</year><pub-id pub-id-type="pmid">29904742</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Morris</surname><given-names>WJ</given-names></name>, <name><surname>Tyldesley</surname><given-names>S</given-names></name>, <name><surname>Rodda</surname><given-names>S</given-names></name>
<etal/>: <article-title>Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source>, <volume>98</volume>: <fpage>275</fpage>, <year>2017</year><pub-id pub-id-type="pmid">28262473</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Kishan</surname><given-names>AU</given-names></name>, <name><surname>Cook</surname><given-names>RR</given-names></name>, <name><surname>Ciezki</surname><given-names>JP</given-names></name>
<etal/>: <article-title>Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9&#x02013;10 Prostate Cancer</article-title>. <source>JAMA</source>, <volume>319</volume>: <fpage>896</fpage>, <year>2018</year><pub-id pub-id-type="pmid">29509865</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Berg</surname><given-names>S</given-names></name>, <name><surname>Cole</surname><given-names>AP</given-names></name>, <name><surname>Krimphove</surname><given-names>MJ</given-names></name>
<etal/>: <article-title>Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer</article-title>. <source>Eur Urol</source>, <volume>75</volume>: <fpage>552</fpage>, <year>2019</year><pub-id pub-id-type="pmid">30420255</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Muralidhar</surname><given-names>V</given-names></name>, <name><surname>Mahal</surname><given-names>BA</given-names></name>, <name><surname>Butler</surname><given-names>S</given-names></name>
<etal/>: <article-title>Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9&#x02013;10 Prostate Cancer</article-title>. <source>J Urol</source>, <volume>202</volume>: <fpage>973</fpage>, <year>2019</year><pub-id pub-id-type="pmid">31144590</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Tilki</surname><given-names>D</given-names></name>, <name><surname>Chen</surname><given-names>MH</given-names></name>, <name><surname>Wu</surname><given-names>J</given-names></name>
<etal/>: <article-title>Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9&#x02013;10 Prostate Cancer and the Risk of Mortality</article-title>. <source>JAMA Oncol</source>, <volume>5</volume>: <fpage>213</fpage>, <year>2019</year><pub-id pub-id-type="pmid">30452521</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Jayadevappa</surname><given-names>R</given-names></name>, <name><surname>Malkowicz</surname><given-names>SB</given-names></name>, <name><surname>Wittink</surname><given-names>M</given-names></name>
<etal/>: <article-title>Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors</article-title>. <source>Health Serv Res</source>, <volume>47</volume>: <fpage>1902</fpage>, <year>2012</year><pub-id pub-id-type="pmid">22417225</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Kishan</surname><given-names>AU</given-names></name>, <name><surname>Shaikh</surname><given-names>T</given-names></name>, <name><surname>Wang</surname><given-names>PC</given-names></name>
<etal/>: <article-title>Clinical Outcomes for Patients with Gleason Score 9&#x02013;10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis</article-title>. <source>Eur Urol</source>, <volume>71</volume>: <fpage>766</fpage>, <year>2017</year><pub-id pub-id-type="pmid">27452951</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Kotronoulas</surname><given-names>G</given-names></name>, <name><surname>Kearney</surname><given-names>N</given-names></name>, <name><surname>Maguire</surname><given-names>R</given-names></name>
<etal/>: <article-title>What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials</article-title>. <source>J Clin Oncol</source>, <volume>32</volume>: <fpage>1480</fpage>, <year>2014</year><pub-id pub-id-type="pmid">24711559</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="webpage"><source>Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer</source>: <comment><ext-link xlink:href="https://ClinicalTrials.gov/show/NCT01326286" ext-link-type="uri">https://ClinicalTrials.gov/show/NCT01326286</ext-link></comment></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Lubeck</surname><given-names>DP</given-names></name>, <name><surname>Litwin</surname><given-names>MS</given-names></name>, <name><surname>Henning</surname><given-names>JM</given-names></name>
<etal/>: <article-title>The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor</article-title>. <source>Urology</source>, <volume>48</volume>: <fpage>773</fpage>, <year>1996</year><pub-id pub-id-type="pmid">8911524</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Szymanski</surname><given-names>KM</given-names></name>, <name><surname>Wei</surname><given-names>JT</given-names></name>, <name><surname>Dunn</surname><given-names>RL</given-names></name>
<etal/>: <article-title>Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors</article-title>. <source>Urology</source>, <volume>76</volume>: <fpage>1245</fpage>, <year>2010</year><pub-id pub-id-type="pmid">20350762</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr.</suffix></name>, <name><surname>Sherbourne</surname><given-names>CD</given-names></name>: <article-title>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</article-title>. <source>Med Care</source>, <volume>30</volume>: <fpage>473</fpage>, <year>1992</year><pub-id pub-id-type="pmid">1593914</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>JA</given-names></name>, <name><surname>Bokhour</surname><given-names>BG</given-names></name>, <name><surname>Inui</surname><given-names>TS</given-names></name>
<etal/>: <article-title>Measuring patients&#x02019; perceptions of the outcomes of treatment for early prostate cancer</article-title>. <source>Med Care</source>, <volume>41</volume>: <fpage>923</fpage>, <year>2003</year><pub-id pub-id-type="pmid">12886172</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Litwin</surname><given-names>MS</given-names></name>, <name><surname>Greenfield</surname><given-names>S</given-names></name>, <name><surname>Elkin</surname><given-names>EP</given-names></name>
<etal/>: <article-title>Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice</article-title>. <source>Cancer</source>, <volume>109</volume>: <fpage>1777</fpage>, <year>2007</year><pub-id pub-id-type="pmid">17354226</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>SH</given-names></name>, <name><surname>Gandek</surname><given-names>B</given-names></name>, <name><surname>Greenfield</surname><given-names>S</given-names></name>
<etal/>: <article-title>Patient and visit characteristics related to physicians&#x02019; participatory decision-making style. Results from the Medical Outcomes Study</article-title>. <source>Med Care</source>, <volume>33</volume>: <fpage>1176</fpage>, <year>1995</year><pub-id pub-id-type="pmid">7500658</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>SH</given-names></name>, <name><surname>Billimek</surname><given-names>J</given-names></name>, <name><surname>Sorkin</surname><given-names>DH</given-names></name>
<etal/>: <article-title>Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects</article-title>. <source>Med Care</source>, <volume>48</volume>: <fpage>S9</fpage>, <year>2010</year><pub-id pub-id-type="pmid">20473205</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Andresen</surname><given-names>EM</given-names></name>, <name><surname>Malmgren</surname><given-names>JA</given-names></name>, <name><surname>Carter</surname><given-names>WB</given-names></name>
<etal/>: <article-title>Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale)</article-title>. <source>Am J Prev Med</source>, <volume>10</volume>: <fpage>77</fpage>, <year>1994</year><pub-id pub-id-type="pmid">8037935</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Sherbourne</surname><given-names>CD</given-names></name>, <name><surname>Stewart</surname><given-names>AL</given-names></name>: <article-title>The MOS social support survey</article-title>. <source>Soc Sci Med</source>, <volume>32</volume>: <fpage>705</fpage>, <year>1991</year><pub-id pub-id-type="pmid">2035047</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Skolarus</surname><given-names>TA</given-names></name>, <name><surname>Dunn</surname><given-names>RL</given-names></name>, <name><surname>Sanda</surname><given-names>MG</given-names></name>
<etal/>: <article-title>Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form</article-title>. <source>Urology</source>, <volume>85</volume>: <fpage>101</fpage>, <year>2015</year><pub-id pub-id-type="pmid">25530370</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="book"><name><surname>Huber</surname><given-names>PJ</given-names></name>: <part-title>The behavior of maximum likelihood estimates under nonstandard conditions</part-title>. <source>Presented at the Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability</source>, Volume <volume>1</volume>: <comment>Statistics</comment>, <publisher-loc>Berkeley, Calif.</publisher-loc>, <year>1967</year>, <fpage>1967</fpage></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>White</surname><given-names>H</given-names></name>: <article-title>A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity</article-title>. <source>Econometrica</source>, <volume>48</volume>: <fpage>817</fpage>, <year>1980</year></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="book"><name><surname>Harrell</surname><given-names>FE</given-names></name>: <source>Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis</source>: <publisher-name>Springer International Publishing</publisher-name>, <year>2015</year></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Lennern&#x000e4;s</surname><given-names>B</given-names></name>, <name><surname>Majumder</surname><given-names>K</given-names></name>, <name><surname>Damber</surname><given-names>JE</given-names></name>
<etal/>: <article-title>Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes</article-title>. <source>Acta Oncol</source>, <volume>54</volume>: <fpage>875</fpage>, <year>2015</year><pub-id pub-id-type="pmid">25362844</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Rodda</surname><given-names>S</given-names></name>, <name><surname>Morris</surname><given-names>WJ</given-names></name>, <name><surname>Hamm</surname><given-names>J</given-names></name>
<etal/>: <article-title>ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source>, <volume>98</volume>: <fpage>581</fpage>, <year>2017</year><pub-id pub-id-type="pmid">28581398</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Parry</surname><given-names>MG</given-names></name>, <name><surname>Nossiter</surname><given-names>J</given-names></name>, <name><surname>Cowling</surname><given-names>TE</given-names></name>
<etal/>: <article-title>Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study</article-title>. <source>Radiotherapy and Oncology</source>, <volume>155</volume>: <fpage>48</fpage>, <year>2021</year><pub-id pub-id-type="pmid">33075390</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Hoffman</surname><given-names>KE</given-names></name>, <name><surname>Penson</surname><given-names>DF</given-names></name>, <name><surname>Zhao</surname><given-names>Z</given-names></name>
<etal/>: <article-title>Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer</article-title>. <source>JAMA</source>, <volume>323</volume>: <fpage>149</fpage>, <year>2020</year><pub-id pub-id-type="pmid">31935027</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>RC</given-names></name>, <name><surname>Basak</surname><given-names>R</given-names></name>, <name><surname>Meyer</surname><given-names>AM</given-names></name>
<etal/>: <article-title>Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer</article-title>. <source>Jama</source>, <volume>317</volume>: <fpage>1141</fpage>, <year>2017</year><pub-id pub-id-type="pmid">28324092</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Reynaud</surname><given-names>T</given-names></name>, <name><surname>Hathout</surname><given-names>L</given-names></name>, <name><surname>Carignan</surname><given-names>D</given-names></name>
<etal/>: <article-title>PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study</article-title>. <source>Brachytherapy</source>, <volume>20</volume>: <fpage>1090</fpage>, <year>2021</year><pub-id pub-id-type="pmid">34238688</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Smile</surname><given-names>TD</given-names></name>, <name><surname>Tom</surname><given-names>MC</given-names></name>, <name><surname>Halima</surname><given-names>A</given-names></name>
<etal/>: <article-title>(125)I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer</article-title>. <source>Brachytherapy</source>, <volume>21</volume>: <fpage>85</fpage>, <year>2022</year><pub-id pub-id-type="pmid">34656435</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1:</label><caption><p id="P83">Unadjusted Expanded Prostate Cancer Index Composite and Short Form Domain Scores Comparing EBRT-LDR vs. RP Through Five Years</p><p id="P84">Unadjusted domain scores (ranging from 0&#x02013;100 with higher scores reflecting better function) were tracked at baseline, 6 months, 1 year, 3 years, and 5 years for EPIC and SF36 surveys. Panels (A) through (E) reflect the EPIC domains such as urinary irritation, urinary incontinence, bowel function, sexual function, and hormone function. Panels (F) through (H) reflect the SF36 domains such as physical function, emotional well-being, and energy/fatigue.</p><p id="P844">All EPIC domains were well-balanced at baseline with the exception of sexual function which was lower in the EBRT-LDR group vs. RP group (65 points [quartiles: 33, 85] vs. 78 points [38, 95]; <italic toggle="yes">P</italic>=0.016). All SF36 domains were well-balanced at baseline with the exception of emotional well-being which was higher in the EBRT-LDR group vs. RP group (86 points [80, 92] vs. 84 points [68, 92]; <italic toggle="yes">P</italic>=0.009).</p><p id="P85">Abbreviations: External beam radiotherapy plus low-dose brachytherapy (EBRT-LDR); radical prostatectomy (RP); 26-item Expanded Prostate Cancer Index Composite (EPIC); 36-item Short Form (SF36).</p></caption><graphic xlink:href="nihms-1872197-f0001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2:</label><caption><p id="P86">Adjusted Expanded Prostate Cancer Index Composite Domain Scores Comparing EBRT-LDR vs. RP Through Five Years</p><p id="P845">Adjusted domain scores for EPIC function (ranging from 0&#x02013;100 with higher scores reflecting better function) were represented through radar plots by comparing baseline to (A) 6 months, (B) 1 year, (C) 3 years, and (D) 5 years in the EBRT-LDR group (blue line) vs. RP group (red line). The EPIC minimum clinically important difference scores were 5&#x02013;7 points for urinary irritative/obstructive function, 6&#x02013;9 points for urinary incontinence, 4&#x02013;6 points for bowel function, 10&#x02013;12 points for sexual function, and 4&#x02013;6 points for hormone function. The outermost part of the radar plot represents best function (score of 100) and the center represents worst function (score of 0). The adjusted domain scores were generated by applying a multivariable linear regression model that accounts for baseline scores and other covariates.</p><p id="P87">EBRT-LDR, when compared to RP, was associated with a clinically meaningful decline in urinary irritative/obstructive function (&#x02212;5-point difference [95% CI &#x02212;8.7, &#x02212;1.3]; <italic toggle="yes">P</italic>=0.008) and bowel function (&#x02212;4-point difference [95% CI &#x02212;6.9, &#x02212;1.1]; <italic toggle="yes">P</italic>=0.006) through 5 years. RP, when compared to EBRT-LDR, was associated with a clinically meaningful decline in urinary incontinence (&#x02212;13.3-point difference [95% CI &#x02212;7.7, &#x02212;18.9]; <italic toggle="yes">P</italic>&#x0003c;0.001) through 5 years and sexual function (&#x02212;12-point difference [95% &#x02212;6.5, &#x02212;17.5]; <italic toggle="yes">P</italic>&#x0003c;0.001) through 1 year.</p><p id="P88">Abbreviations: External beam radiotherapy plus low-dose brachytherapy (EBRT-LDR); radical prostatectomy (RP); 26-item Expanded Prostate Cancer Index Composite (EPIC); 36-item Short Form (SF36); 95% confidence interval (95% CI).</p></caption><graphic xlink:href="nihms-1872197-f0002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3:</label><caption><p id="P89">Adjusted Short Form Domain Scores Comparing EBRT-LDR vs. Radical Prostatectomy Through Five Years</p><p id="P90">Adjusted domain scores for SF36 function (ranging from 0&#x02013;100 with higher scores reflecting better function) were represented through radar plots by comparing baseline to (A) 6 months, (B) 1 year, (C) 3 years, and (D) 5 years in the EBRT-LDR group (blue line) vs. RP group (red line). The SF36 minimum clinically important difference scores were 7 points for physical function, 6 points for emotional well-being, and 9 points for energy/fatigue. The outermost part of the radar plot represents best function (score of 100) and the center represents worst function (score of 0). The adjusted domain scores were generated by applying a multivariable linear regression model that accounts for baseline scores and other covariates. There were no clinically meaningful changes in SF36 function between the two groups through 5 years.</p><p id="P846">Abbreviations: External beam radiotherapy plus low-dose brachytherapy (EBRT-LDR); radical prostatectomy (RP); 36-item Short Form (SF36).</p></caption><graphic xlink:href="nihms-1872197-f0003" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1:</label><caption><p id="P91">Baseline Participant and Treatment Clinical Characteristics</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">EBRT-LDR<break/>(n=112)</th><th align="center" valign="middle" rowspan="1" colspan="1">RP<break/>(n=1533)</th><th align="center" valign="middle" rowspan="1" colspan="1">Combined<break/>(n=1645)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value<xref rid="TFN1" ref-type="table-fn">*</xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at diagnosis, median (Q<sub>1</sub>, Q<sub>3</sub>)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">66 (60, 71)</td><td align="center" valign="middle" rowspan="1" colspan="1">62 (57, 66)</td><td align="center" valign="middle" rowspan="1" colspan="1">62 (57, 67)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race</td><td align="left" valign="middle" rowspan="1" colspan="1">White</td><td align="center" valign="middle" rowspan="1" colspan="1">82 (74%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1136 (75%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1218 (75%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Black</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (21%)</td><td align="center" valign="middle" rowspan="1" colspan="1">190 (12%)</td><td align="center" valign="middle" rowspan="1" colspan="1">213 (13%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Hispanic</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">125 (8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">128 (8%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (3%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (2%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education</td><td align="left" valign="middle" rowspan="1" colspan="1">Less than high school</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">131 (9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">137 (9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">High school graduate</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (21%)</td><td align="center" valign="middle" rowspan="1" colspan="1">302 (21%)</td><td align="center" valign="middle" rowspan="1" colspan="1">323 (21%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Some college</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (26%)</td><td align="center" valign="middle" rowspan="1" colspan="1">316 (22%)</td><td align="center" valign="middle" rowspan="1" colspan="1">342 (22%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">College graduate</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (23%)</td><td align="center" valign="middle" rowspan="1" colspan="1">345 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">368 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Graduate/professional school</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">351 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">375 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Marital status</td><td align="left" valign="middle" rowspan="1" colspan="1">Not married</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (23%)</td><td align="center" valign="middle" rowspan="1" colspan="1">246 (17%)</td><td align="center" valign="middle" rowspan="1" colspan="1">269 (17%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Married</td><td align="center" valign="middle" rowspan="1" colspan="1">78 (77%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1196 (83%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1274 (83%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total Illness Burden Index for Prostate Cancer<sup><xref rid="TFN2" ref-type="table-fn">a</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">0&#x02013;2</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">483 (33%)</td><td align="center" valign="middle" rowspan="1" colspan="1">507 (33%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">3&#x02013;4</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (48%)</td><td align="center" valign="middle" rowspan="1" colspan="1">625 (43%)</td><td align="center" valign="middle" rowspan="1" colspan="1">674 (43%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;5</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (28%)</td><td align="center" valign="middle" rowspan="1" colspan="1">344 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">373 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D&#x02019;Amico risk grouping<sup><xref rid="TFN3" ref-type="table-fn">b</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">Low Risk</td><td align="center" valign="middle" rowspan="1" colspan="1">35 (31%)</td><td align="center" valign="middle" rowspan="1" colspan="1">640 (42%)</td><td align="center" valign="middle" rowspan="1" colspan="1">675 (41%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Intermediate Risk</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (45%)</td><td align="center" valign="middle" rowspan="1" colspan="1">637 (42%)</td><td align="center" valign="middle" rowspan="1" colspan="1">687 (42%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">High Risk</td><td align="center" valign="middle" rowspan="1" colspan="1">27 (24%)</td><td align="center" valign="middle" rowspan="1" colspan="1">254 (17%)</td><td align="center" valign="middle" rowspan="1" colspan="1">281 (17%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PSA at diagnosis, corrected</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;4</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (15%)</td><td align="center" valign="middle" rowspan="1" colspan="1">301 (20%)</td><td align="center" valign="middle" rowspan="1" colspan="1">318 (19%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;4 to &#x0003c;10</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (76%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1058 (69%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1143 (69%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;10 to &#x0003c;20</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">134 (9%)</td><td align="center" valign="middle" rowspan="1" colspan="1">142 (9%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;20 to &#x0003c;50</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (3%)</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (3%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clinical tumor stage</td><td align="left" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (77%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1147 (75%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1233 (75%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (23%)</td><td align="center" valign="middle" rowspan="1" colspan="1">383 (25%)</td><td align="center" valign="middle" rowspan="1" colspan="1">409 (25%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gleason score on biopsy</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02264;6</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (34%)</td><td align="center" valign="middle" rowspan="1" colspan="1">750 (49%)</td><td align="center" valign="middle" rowspan="1" colspan="1">788 (48%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">3 + 4</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (36%)</td><td align="center" valign="middle" rowspan="1" colspan="1">460 (30%)</td><td align="center" valign="middle" rowspan="1" colspan="1">500 (30%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">4 + 3</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">170 (11%)</td><td align="center" valign="middle" rowspan="1" colspan="1">182 (11%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;8</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (20%)</td><td align="center" valign="middle" rowspan="1" colspan="1">149 (10%)</td><td align="center" valign="middle" rowspan="1" colspan="1">171 (10%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Accrual site</td><td align="left" valign="middle" rowspan="1" colspan="1">Site 1</td><td align="center" valign="bottom" rowspan="1" colspan="1">1 (1%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">128 (8%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">129 (8%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Site 2</td><td align="center" valign="bottom" rowspan="1" colspan="1">86 (77%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">196 (13%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">282 (17%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Site 3</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (2%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">447 (29%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">449 (27%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Site 4</td><td align="center" valign="bottom" rowspan="1" colspan="1">15 (13%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">395 (26%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">410 (25%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Site 5</td><td align="center" valign="bottom" rowspan="1" colspan="1">3 (3%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">245 (16%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">248 (15%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Site 6</td><td align="center" valign="bottom" rowspan="1" colspan="1">5 (4%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">122 (8%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">127 (8%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any ADT in first year after treatment</td><td align="left" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (16%)</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (84%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1442 (95%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1535 (94%)</td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Participatory decision-making scale, median (Q<sub>1</sub>, Q<sub>3</sub>)<sup><xref rid="TFN4" ref-type="table-fn">c</xref></sup></td><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">79 (71, 89)</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (71, 93)</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (71, 93)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Provider-dependent health care orientation scale, median (Q<sub>1</sub>, Q<sub>3</sub>)<sup><xref rid="TFN5" ref-type="table-fn">d</xref></sup></td><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">17 (6, 35)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (8, 38)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (8, 38)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Social support scale, median (Q<sub>1</sub>, Q<sub>3</sub>)<sup><xref rid="TFN6" ref-type="table-fn">e</xref></sup></td><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">95 (75, 100)</td><td align="center" valign="middle" rowspan="1" colspan="1">95 (75, 100)</td><td align="center" valign="middle" rowspan="1" colspan="1">95 (75, 100)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Depression scale, median (Q<sub>1</sub>, Q<sub>3</sub>)<sup><xref rid="TFN7" ref-type="table-fn">f</xref></sup></td><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">11 (4, 22)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (4, 30)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (4, 30)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Surgery type</td><td align="left" valign="top" rowspan="1" colspan="1">None</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">95 (9%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Unilateral nerve-sparing</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">128 (12%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Bilateral nerve-sparing</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">859 (79%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Received pelvic radiation</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">10 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">95 (90%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Received IMRT</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">89 (85%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">16 (15%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Received IGRT</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">77 (79%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">20 (21%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EBRT dose per fraction</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02264;2 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">91 (99%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">2&#x02013;3 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;3 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median EBRT radiation dose (Q<sub>1</sub>, Q<sub>3</sub>), Gy</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">45 (45, 52.5)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number receiving I-125 (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">86 (84%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median I-125 dose (Q<sub>1</sub>, Q<sub>3</sub>), Gy</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">91 (80, 110)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number receiving Pd-103 (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">16 (16%)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median Pd-103 dose (Q<sub>1</sub>, Q<sub>3</sub>), Gy</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">100 (92, 100)</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td><td align="center" valign="top" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P92">Assessed EBRT-LDR vs. RP group using either a Wilcoxon test for continuous variables or Pearson <italic toggle="yes">Chi</italic>-squared test for categorical variables.</p></fn><fn id="TFN2"><label>a</label><p id="P93">Measures patient illness and co-morbidity burden, with higher scores reflecting greater severity and number of co-morbidities.</p></fn><fn id="TFN3"><label>b</label><p id="P94">Classified by D&#x02019;Amico risk grouping: Low risk defined as Gleason score &#x0003c;6 and PSA &#x0003c;10 ng/mL and clinical stage T1c-T2a; intermediate risk defined as Gleason score 7 or PSA 10&#x02013;20 ng/mL or clinical stage T2b; high risk defined as Gleason score 8 or PSA &#x0003e;20 ng/mL or clinical stage T2c-T3.</p></fn><fn id="TFN4"><label>c</label><p id="P95">Measures patient decision-making style (scale 0&#x02013;100) using the Provider-Dependent Health Care Orientation Scale, with higher scores reflecting increased patient choice, control, and responsibility.</p></fn><fn id="TFN5"><label>d</label><p id="P96">Measures patient decision-making passivity (scale 0&#x02013;100) using the Participatory Decision-Making Scale, with higher scores reflecting increased passivity.</p></fn><fn id="TFN6"><label>e</label><p id="P97">Measures degree of social support (scale 0&#x02013;100) using the Medical Outcomes Study Social Support Scale, with higher scores reflecting greater support.</p></fn><fn id="TFN7"><label>f</label><p id="P98">Measures patient depression (scale 0&#x02013;100) using the Epidemiologic Studies Depression Scale, with higher scores reflecting more severe depressive symptoms.</p></fn><fn id="TFN8"><p id="P99">Abbreviations: External beam radiotherapy plus low-dose brachytherapy (EBRT-LDR); radical prostatectomy (RP); prostate-specific antigen (PSA); androgen deprivation therapy (ADT); intensity modulated radiotherapy (IMRT); image-guided radiotherapy (IGRT); Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), 1<sup>st</sup> and 3<sup>rd</sup> quartiles (Q<sub>1 ,</sub> Q<sub>3</sub>).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="landscape"><label>Table 2:</label><caption><p id="P100">Unadjusted and Adjusted Patient-Reported Outcomes on the Expanded Prostate Cancer Index Composite Domain Scores Stratified by Treatment Group and Time Point</p></caption><table frame="box" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" style="border-right: solid 1px" rowspan="1" colspan="1">Time</th><th align="center" valign="middle" rowspan="1" colspan="1">EBRT-LDR</th><th align="center" valign="middle" rowspan="1" colspan="1">RP</th><th align="center" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="middle" rowspan="1">EBRT-LDR vs. RP</th></tr><tr><th align="left" valign="top" style="border-right: solid 1px" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">(N=112)</th><th align="center" valign="middle" rowspan="1" colspan="1">(N=1533)</th><th align="center" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value<sup><xref rid="TFN10" ref-type="table-fn">a</xref></sup></th><th align="center" valign="middle" rowspan="1" colspan="1">Effect</th><th align="center" valign="middle" rowspan="1" colspan="1">[95% CI]</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr style="border-bottom: solid 1px"><td align="left" valign="top" rowspan="1" colspan="1">EPIC Urinary Function Domains<sup><xref rid="TFN10" ref-type="table-fn">a</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" style="border-right: solid 1px" rowspan="1" colspan="1">
<bold>Urinary irritative/obstructive</bold>
</td><td colspan="3" align="center" valign="middle" style="border-right: solid 1px" rowspan="1">Unadjusted median (Q<sub>1</sub>, Q<sub>3</sub>) domain score</td><td colspan="3" align="center" valign="middle" rowspan="1">Adjusted linear model; effect size = point difference between groups</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Baseline</td><td align="center" valign="bottom" rowspan="1" colspan="1">91 (75, 95)</td><td align="center" valign="bottom" rowspan="1" colspan="1">88 (75, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.446</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">6 months</td><td align="center" valign="bottom" rowspan="1" colspan="1">75 (56, 88)</td><td align="center" valign="bottom" rowspan="1" colspan="1">94 (81, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;16.3<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;19.9, &#x02212;12.7]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">1 year</td><td align="center" valign="bottom" rowspan="1" colspan="1">81 (66, 88)</td><td align="center" valign="bottom" rowspan="1" colspan="1">94 (81, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;13.4<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;17.6, &#x02212;9.2]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">3 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">88 (75, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">94 (88, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;6.9<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;10.6, &#x02212;3.2]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="bottom" rowspan="1" colspan="1">5 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">88 (75, 94)</td><td align="center" valign="bottom" rowspan="1" colspan="1">94 (88, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;5.0<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;8.7, &#x02212;1.3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.008</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" style="border-right: solid 1px" rowspan="1" colspan="1">
<bold>Urinary Incontinence</bold>
</td><td colspan="3" align="center" valign="middle" style="border-right: solid 1px" rowspan="1">Unadjusted median (Q<sub>1</sub>, Q<sub>3</sub>) domain score</td><td colspan="3" align="center" valign="middle" rowspan="1">Adjusted linear model; effect size = point difference between groups</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Baseline</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (85, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (79, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.481</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">6 months</td><td align="center" valign="bottom" rowspan="1" colspan="1">94 (73, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">67 (46, 94)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">24.2<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[20.1, 28.2]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">1 year</td><td align="center" valign="bottom" rowspan="1" colspan="1">92 (73, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">75 (52, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">15.1<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[11.0, 19.2]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">3 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">94 (73, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">75 (54, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">12.8<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[8.0, 17.6]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="bottom" rowspan="1" colspan="1">5 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">92 (73, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">73 (52, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">13.3<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[7.7, 18.9]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" rowspan="1" colspan="1">EPIC Bowel Function Domain<sup><xref rid="TFN10" ref-type="table-fn">a</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" style="border-right: solid 1px" rowspan="1" colspan="1">
<bold>Bowel Function</bold>
</td><td colspan="3" align="center" valign="middle" style="border-right: solid 1px" rowspan="1">Unadjusted median (Q<sub>1</sub>, Q<sub>3</sub>) domain score</td><td colspan="3" align="center" valign="middle" rowspan="1">Adjusted linear model; effect size = point difference between groups</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Baseline</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (92, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (92, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.75</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">6 months</td><td align="center" valign="bottom" rowspan="1" colspan="1">92 (79, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (96, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;7.1<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;10.4, &#x02212;3.9]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">1 year</td><td align="center" valign="bottom" rowspan="1" colspan="1">92 (79, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (96, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;9.1<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;11.9, &#x02212;6.4]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">3 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">96 (83, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (96, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;6.3<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;9.4, &#x02212;3.1]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="bottom" rowspan="1" colspan="1">5 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">92 (83, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">100 (96, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;4.0<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;6.9, &#x02212;1.1]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.006</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" rowspan="1" colspan="1">EPIC Sexual Function Domain<sup><xref rid="TFN10" ref-type="table-fn">a</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" style="border-right: solid 1px" rowspan="1" colspan="1">
<bold>Sexual function</bold>
</td><td colspan="3" align="center" valign="middle" style="border-right: solid 1px" rowspan="1">Unadjusted median (Q<sub>1</sub>, Q<sub>3</sub>) domain score</td><td colspan="3" align="center" valign="middle" rowspan="1">Adjusted linear model; effect size = point difference between groups</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Baseline</td><td align="center" valign="bottom" rowspan="1" colspan="1">65 (33, 85)</td><td align="center" valign="bottom" rowspan="1" colspan="1">78 (38, 95)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.016</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">6 months</td><td align="center" valign="bottom" rowspan="1" colspan="1">38 (6, 70)</td><td align="center" valign="bottom" rowspan="1" colspan="1">22 (5, 53)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.011</td><td align="center" valign="bottom" rowspan="1" colspan="1">15.2<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[9.1, 21.3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">1 year</td><td align="center" valign="bottom" rowspan="1" colspan="1">40 (7, 70)</td><td align="center" valign="bottom" rowspan="1" colspan="1">28 (7, 65)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.252</td><td align="center" valign="bottom" rowspan="1" colspan="1">12.0<xref rid="TFN9" ref-type="table-fn">*</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">[6.5, 17.5]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">3 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">37 (7, 70)</td><td align="center" valign="bottom" rowspan="1" colspan="1">33 (10, 70)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.721</td><td align="center" valign="bottom" rowspan="1" colspan="1">6.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.1, 12.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.046</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="bottom" rowspan="1" colspan="1">5 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">38 (7, 75)</td><td align="center" valign="bottom" rowspan="1" colspan="1">35 (7, 73)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.774</td><td align="center" valign="bottom" rowspan="1" colspan="1">6.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;0.1, 13.4]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.052</td></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" rowspan="1" colspan="1">EPIC Hormone Function Domain<sup><xref rid="TFN10" ref-type="table-fn">a</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr style="border-bottom: solid 1px"><td align="left" valign="top" style="border-right: solid 1px" rowspan="1" colspan="1">
<bold>Hormone function</bold>
</td><td colspan="3" align="center" valign="middle" style="border-right: solid 1px" rowspan="1">Unadjusted median (Q<sub>1</sub>, Q<sub>3</sub>) domain score</td><td colspan="3" align="center" valign="middle" rowspan="1">Adjusted linear model; effect size = point difference between groups</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Baseline</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (85, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (85, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.484</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td><td align="center" valign="bottom" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">6 months</td><td align="center" valign="bottom" rowspan="1" colspan="1">90 (80, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (85, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.048</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;5.7, &#x02212;0.3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">1 year</td><td align="center" valign="bottom" rowspan="1" colspan="1">90 (80, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (81, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.085</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;0.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;3.3, 2.8]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.877</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">3 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (85, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (85, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.868</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.6</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;1.5, 4.7]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.321</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">5 years</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (85, 100)</td><td align="center" valign="bottom" rowspan="1" colspan="1">95 (85, 100)</td><td align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1">0.828</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.8</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#x02212;1.2, 4.8]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.249</td></tr></tbody></table><table-wrap-foot><fn id="TFN9"><label>*</label><p id="P101">Represents a clinically meaningful difference defined as meeting statistical significance and clinical significance. Clinical significance is defined as the difference between groups exceeding the MCID. EPIC MCID was defined as 5&#x02013;7 points for urinary irritative/obstructive, 6&#x02013;9 points for urinary incontinence, 4&#x02013;6 points for bowel function, 10&#x02013;12 points for sexual function, and 4&#x02013;6 points for hormonal function.</p></fn><fn id="TFN10"><label>a</label><p id="P102">Domain scores for EPIC are represented as unadjusted values in the left column, scaled from 0 to 100 with higher scores representing better function. Unadjusted scores are represented as median values with interquartile range (25<sup>th</sup> percentile, 75<sup>th</sup> percentile). The right column values are based on a multivariable regression model with the effect size representing the adjusted mean point difference using surgery as the reference group. Effect size negative values reflect worse patient-reported outcomes in the EBRT-LDR group while positive values reflect better patient-reported outcomes in the EBRT-LDR group. The multivariable linear regression model was adjusted for age, race, comorbidities, disease risk classification, use of androgen deprivation therapy, use of pelvic radiation therapy, depression scores, decision-making style scores, social support scores, time from treatment, geographic site of treatment, and corresponding baseline scores.</p></fn><fn id="TFN11"><p id="P103">Abbreviations: External beam radiotherapy plus low-dose brachytherapy (EBRT-LDR); radical prostatectomy (RP); 95% confidence interval (95% CI); adjusted odds ratio (aOR); 26-item Expanded Prostate Cancer Index Composite (EPIC); minimum clinically important difference (MCID); 1<sup>st</sup> and 3<sup>rd</sup> quartiles (Q<sub>1,</sub> Q<sub>3</sub>).</p></fn></table-wrap-foot></table-wrap></floats-group></article>